About Tute Genomics
Tute Genomics is a Healthcare company based in Los Angeles (United States) founded in 2012, and was acquired by PierianDx in October 2016. Cloud-based genome analysis for precision medicine is provided. Tute Genomics has raised $7.39 million across 4 funding rounds from investors including Tencent, Intermountain Healthcare and Wellfound. Tute Genomics has completed 1 acquisition, including Knome. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Denali Therapeutics, MiRagen and Poseida Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Tute Genomics offers clinical-grade web-based application, powered by machine learning algorithms that allow researchers and clinicians to analyze, utilize, and interpret human genomes data for scientific discovery and individualized treatment. The companys platform also supports disease gene finding and biomarker discovery, as well as provides machine intelligence, genome management, data filtration for streamlined output, and association analysis. Its platform serves pharmaceuticals and biotechnology companies, genetics laboratories, and research centers.
- Headquarters Los Angeles, United States
- Stage Acquired
- SectorsHealthcare
- Website tutegenomics.com
- Social LinkedIn X Facebook
- Acquired by PierianDx (Oct 2016)
Funding Insights of Tute Genomics
Tute Genomics has successfully raised a total of $7.39M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $868.53 thousand completed in October 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.39M
- Total Rounds 4
- Last Round Series A — $868,532
- First Round $300,000
(Dec 2013)
- Investors Count 6
All 4 funding rounds of Tute Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2015 | $868,532 | Series A | – | – | – |
| Jun 2015 | $3.92M | Series A | – | Intermountain Healthcare, Healthbox | |
| Dec 2014 | $2.3M | Series A | – | Eurovestech | |
| Dec 2013 | $300,000 | Seed | – | – |
7 investors in total: 7 institutional.
Investors in Tute Genomics
Tute Genomics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Tencent, Intermountain Healthcare and Wellfound.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage tech investments are directed by Eurovestech across multiple sectors. | 2000 | eurovestech.com | Pinner, United Kingdom | |
Healthcare startups are accelerated via a five-day program by Healthbox. | 2010 | healthbox.com | Chicago, United States | |
Investments are directed toward early-stage tech startups by Album VC. | album.vc | Lehi, United States | ||
Healthcare services are delivered through integrated hospital networks. | 2002 | intermountainhealthcare.org | United States | |
Value-added internet, mobile, and telecom services are provided in China. | 1998 | tencent.com | Shenzhen, China | |
Startup jobs are connected to individuals via a dedicated platform. | 2013 | wellfound.com | New York, United States | |
Genetic tests for individualized disease diagnosis are provided. | 2014 | pieriandx.com | Saint Louis, United States |
Investor details for Tute Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tute Genomics
Tute Genomics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Knome.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Human genome interpretation software and services are provided. | knome.com | Cambridge, United States | 2007 | Nov 2015 | •••• |
Complete acquisition details for Tute Genomics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Tute Genomics
Competitors of Tute Genomics
Tute Genomics has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, MiRagen and Poseida Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies |
Detailed competitors of Tute Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Tute Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tute Genomics
Complete news archive for Tute Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tute Genomics
Tute Genomics was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Tute Genomics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Tute Genomics is a funded company, having raised a total of $7.39M across 4 funding rounds to date. The company's 1st funding round was a Seed of $300K, raised on Dec 2013.
Tute Genomics offers clinical-grade web-based application, powered by machine learning algorithms that allow researchers and clinicians to analyze, utilize, and interpret human genomes data for scientific discovery and individualized treatment. The companys platform also supports disease gene finding and biomarker discovery, as well as provides machine intelligence, genome management, data filtration for streamlined output, and association analysis. Its platform serves pharmaceuticals and biotechnology companies, genetics laboratories, and research centers.
Tute Genomics's top competitors include Poseida Therapeutics, Denali Therapeutics and MiRagen.
Tute Genomics has made 1 acquisition, including Knome.
Tute Genomics has 7 investors. Key investors include Tencent, Intermountain Healthcare, Wellfound, PierianDx, and Eurovestech.
Yes. Tute Genomics was acquired by PierianDx in October 2016.